u/Busy_Negotiation_681

The author argues SLS is a high-risk biotech with major red flags: a CEO whose MD comes from a known degree mill and whose prior biotech ventures ended in bankruptcy after failed Phase 3 trials, zero backing from reputable biotech hedge funds, and a Phase 3 trial for a 20-year-old molecule that has gained no big pharma interest. The author claims retail pumpers who previously promoted the stock have flipped positions, bought puts, and are shorting to profit from a panic sell-off. Main risk is that the Phase 3 trial could still succeed despite these concerns.